GlassScriptPhysician profile
Mary E Knotts
NPI 1487380499
$3,323.41
in general payments reported to CMS, 2019-2025
54 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $986 · 2023: $1,443 · 2024: $642 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946 · Education: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,946.39 |
| Education | $391.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $207.62 | 2023-2024 | Xospata |
| Janssen Biotech, INC. | $207.36 | 2022-2024 | Akeega, Balversa, Rybrevant |
| Pfizer INC. | $192.35 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $171.65 | 2022-2024 | Opdivo |
| Amgen INC. | $168.21 | 2022 | |
| Genmab U.S., INC. | $144.19 | 2023-2025 | Tivdak |
| Karyopharm Therapeutics INC. | $131.89 | 2022 | |
| Abbvie INC. | $114.05 | 2023-2024 | |
| Aveo Pharmaceuticals, INC. | $99.95 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $96.53 | 2022-2025 | |
| Stemline Therapeutics INC. | $83.96 | 2023 | Orserdu |
| Alexion Pharmaceuticals, INC. | $83.15 | 2023-2024 | Ultomiris |
| Seagen INC. | $81.56 | 2022-2023 | Adcetris |
| Merck Sharp & Dohme LLC | $79.18 | 2023-2025 | Keytruda, Keytruda Qlex |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $76.30 | 2022 | |
| Genzyme Corporation | $75.61 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.06 | 2022-2023 | |
| Pharmacosmos Therapeutics INC. | $65.87 | 2023-2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $64.18 | 2023-2024 | Fruzaqla, Alunbrig, Ninlaro |
| Adaptive Biotechnologies Corporation | $63.89 | 2023-2024 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $62.36 | 2023 | Calquence |
| Daiichi Sankyo INC. | $61.13 | 2022-2023 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $59.39 | 2023-2024 | Libtayo |
| Eisai INC. | $43.98 | 2022-2023 | |
| Novocure INC. | $40.46 | 2023-2024 | Optune Lua (Novottf-200t), Optune |
| Incyte Corporation | $40.24 | 2023-2024 | Jakafi |
| G1 Therapeutics, INC. | $40.15 | 2023 | Cosela |
| Tersera Therapeutics LLC | $39.75 | 2022 | |
| Rigel Pharmaceuticals, INC. | $35.84 | 2022-2023 | Rezlidhia, Tavalisse |
| Emd Serono, INC. | $34.37 | 2023-2024 | Bavencio |
| Genentech USA, INC. | $30.28 | 2023-2024 | Alecensa, Tecentriq, Rozlytrek |
| Sobi, INC | $30.15 | 2022-2023 | |
| Beigene USA, INC. | $29.11 | 2022-2023 | Brukinsa |
| Glaxosmithkline, LLC. | $27.55 | 2022 | |
| Tempus Ai, INC | $27.14 | 2025 | Xt Cdx |
| Foundation Medicine, INC. | $26.87 | 2023 | Foundationone Liquid Cdx |
| Alnylam Pharmaceuticals INC. | $24.52 | 2023 | Onpattro |
| Adc Therapeutics America, INC. | $23.55 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.50 | 2023 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $20.72 | 2023 | Tazverik |
| Celgene Corporation | $19.58 | 2023 | Pomalyst |
| Fennec Pharmaceuticals, INC. | $19.34 | 2024 | Pedmark |
| Taiho Oncology, INC. | $19.32 | 2023 | |
| Aadi Bioscience, INC. | $19.17 | 2023 | Fyarro |
| Array Biopharma INC | $19.00 | 2024 | Braftovi, Lorbrena, Xalkori |
| Apellis Pharmaceuticals, INC. | $18.42 | 2023 | Empaveli |
| Puma Biotechnology, INC. | $17.49 | 2023 | |
| Immunogen, INC. | $17.12 | 2023 | Elahere |
| Gilead Sciences, INC. | $17.06 | 2022 | |
| Cti Biopharma Corp. | $16.68 | 2022 | |
| Deciphera Pharmaceuticals INC. | $15.51 | 2023 | Qinlock |
| Global Blood Therapeutics, INC. | $14.10 | 2022 | |
| Morphosys, US INC. | $14.00 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Knotts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.